Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
Sangeeta Goswami, … , Hao Zhao, Padmanee Sharma
Sangeeta Goswami, … , Hao Zhao, Padmanee Sharma
Published June 15, 2018
Citation Information: J Clin Invest. 2018;128(9):3813-3818. https://doi.org/10.1172/JCI99760.
View: Text | PDF
Concise Communication Immunology Oncology

Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

  • Text
  • PDF
Abstract

Enhancer of zeste homolog 2–mediated (EZH2-mediated) epigenetic regulation of T cell differentiation and Treg function has been described previously; however, the role of EZH2 in T cell–mediated antitumor immunity, especially in the context of immune checkpoint therapy, is not understood. Here, we showed that genetic depletion of EZH2 in Tregs (FoxP3creEZH2fl/fl mice) leads to robust antitumor immunity. In addition, pharmacological inhibition of EZH2 in human T cells using CPI-1205 elicited phenotypic and functional alterations of the Tregs and enhanced cytotoxic activity of Teffs. We observed that ipilimumab (anti–CTLA-4) increased EZH2 expression in peripheral T cells from treated patients. We hypothesized that inhibition of EZH2 expression in T cells would increase the effectiveness of anti–CTLA-4 therapy, which we tested in murine models. Collectively, our data demonstrated that modulating EZH2 expression in T cells can improve antitumor responses elicited by anti–CTLA-4 therapy, which provides a strong rationale for a combination trial of CPI-1205 plus ipilimumab.

Authors

Sangeeta Goswami, Irina Apostolou, Jan Zhang, Jill Skepner, Swetha Anandhan, Xuejun Zhang, Liangwen Xiong, Patrick Trojer, Ana Aparicio, Sumit K. Subudhi, James P. Allison, Hao Zhao, Padmanee Sharma

×

Figure 1

EZH2 inhibition by CPI-1205 enhances T cell–mediated antitumor immunity.

Options: View larger image (or click on image) Download as PowerPoint
EZH2 inhibition by CPI-1205 enhances T cell–mediated antitumor immunity....
Tumor growth (A) and percentages of intratumoral CD8+IFN-γ+ cells, CD8+GzB+ cells, and CD8+TNF-α+ (B) and FoxP3+IFN-γ+ cells (C) in MB49 tumor-bearing EZH2fl/+ (n = 10) and FoxP3CreEZH2fl/fl (n = 10) mice. (D) Differentiated human iTregs with or without CPI-1205 were cultured with CellTrace Violet–labeled Teffs for 72 hours at various ratios. Data are presented as CellTrace Violet+ proliferating Teffs at different concentrations of CPI-1205. (E) Preactivated human CD4+ and CD8+ T cells (with or without CPI-1205) were cultured with CellTrace Violet–labeled Nalm-6 target cells along with blinatumomab. Data are presented as percentages of Annexin+ 7AAD+ cells at various ratios of effector/target cells. Data are representative of 3 independent experiments. A 2-tailed Student’s t test was used to determine significance; **P < 0.01.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts